Pathophysiological Basis and Pharmacological Profile

• Chronic packed red blood cell (PRBC) transfusions in hemoglobinopathies lead to massive secondary iron overload, as each unit contains 200-250 mg of elemental iron.
• Non-transfusion-dependent thalassemia (NTDT) causes hepcidin suppression and subsequent dietary iron hyperabsorption.
• Toxic non-transferrin-bound iron generates massive oxidative stress via the Fenton reaction, leading to restrictive cardiomyopathy, cirrhosis, and endocrinopathies.
• Deferasirox (DFX) is a tridentate oral iron chelator that binds ferric iron in a 2:1 ratio.
• DFX possesses an 8-16 hour plasma half-life permitting once-daily dosing and relies on hepatobiliary excretion.

Formulation Paradigm Shift

• Global protocols have completely transitioned from Dispersible Tablets (DT) to Film-Coated Tablets (FCT).

Recent Guidelines for Initiation and Monitoring (2025-2026)

• Indian Society of Haematology and Blood Transfusion (ISHBT) 2026 guidelines mandate chelation initiation after 10-20 PRBC transfusions or when serum ferritin consistently exceeds 1000 ng/mL.
• The maintenance target is a serum ferritin level of 500-1000 ng/mL.
• Ferritin levels below 300 ng/mL drastically increase the risk of DFX-induced renal toxicity due to the stripping of functional iron from metalloenzymes.

Breakthrough Combinations and Adjuncts

• Dual Oral Iron Chelation (DOIC): Combines DFX and Deferiprone (DFP) for refractory cases. DFP acts as an intracellular shuttle extracting mitochondrial iron, while DFX acts as a plasma sink. DOIC is now the preferred rescue therapy for iron overload cardiomyopathy.
• Amlodipine Adjuvant: This L-type voltage-dependent calcium channel blocker physically prevents toxic iron entry into cardiomyocytes, significantly improving cardiac T2* by an average of 2.79 milliseconds.
• Gene Therapy Pre-Conditioning: Maximal DFX therapy is strictly mandated prior to CRISPR/Cas9 gene therapy to reduce hepatic iron and prevent lethal hepatic veno-occlusive disease during busulfan conditioning.

Toxicity and Surveillance Protocols

• Tissue Iron Quantification: MRI T2* is the gold standard; a cardiac T2* < 10 milliseconds indicates severe myocardial siderosis and a high risk of sudden cardiac death.
• Renal Toxicity: DFX can cause reversible creatinine elevation and Fanconi syndrome; baseline creatinine clearance, weekly serum creatinine, and urine protein/creatinine ratios are mandatory initially.
• Hepatic Toxicity: Requires transaminase monitoring every two weeks during the first month, then monthly.
• Gastrointestinal Toxicity: Severe mucosal ulceration and hemorrhage require immediate drug cessation if suspected.
• Sensory Toxicity: Annual audiograms and slit-lamp examinations are standard of care to monitor for high-frequency sensorineural hearing loss and cataracts.# Iron Chelation Therapy Updates

Pathophysiological Basis and Pharmacological Profile

• Chronic packed red blood cell (PRBC) transfusions in hemoglobinopathies lead to massive secondary iron overload, as each unit contains 200-250 mg of elemental iron.
• Non-transfusion-dependent thalassemia (NTDT) causes hepcidin suppression and subsequent dietary iron hyperabsorption.
• Toxic non-transferrin-bound iron generates massive oxidative stress via the Fenton reaction, leading to restrictive cardiomyopathy, cirrhosis, and endocrinopathies.
• Deferasirox (DFX) is a tridentate oral iron chelator that binds ferric iron in a 2:1 ratio.
• DFX possesses an 8-16 hour plasma half-life permitting once-daily dosing and relies on hepatobiliary excretion.

Formulation Paradigm Shift

• Global protocols have completely transitioned from Dispersible Tablets (DT) to Film-Coated Tablets (FCT).

Recent Guidelines for Initiation and Monitoring (2025-2026)

• Indian Society of Haematology and Blood Transfusion (ISHBT) 2026 guidelines mandate chelation initiation after 10-20 PRBC transfusions or when serum ferritin consistently exceeds 1000 ng/mL.
• The maintenance target is a serum ferritin level of 500-1000 ng/mL.
• Ferritin levels below 300 ng/mL drastically increase the risk of DFX-induced renal toxicity due to the stripping of functional iron from metalloenzymes.

Breakthrough Combinations and Adjuncts

• Dual Oral Iron Chelation (DOIC): Combines DFX and Deferiprone (DFP) for refractory cases. DFP acts as an intracellular shuttle extracting mitochondrial iron, while DFX acts as a plasma sink. DOIC is now the preferred rescue therapy for iron overload cardiomyopathy.
• Amlodipine Adjuvant: This L-type voltage-dependent calcium channel blocker physically prevents toxic iron entry into cardiomyocytes, significantly improving cardiac T2* by an average of 2.79 milliseconds.
• Gene Therapy Pre-Conditioning: Maximal DFX therapy is strictly mandated prior to CRISPR/Cas9 gene therapy to reduce hepatic iron and prevent lethal hepatic veno-occlusive disease during busulfan conditioning.

Toxicity and Surveillance Protocols

• Tissue Iron Quantification: MRI T2* is the gold standard; a cardiac T2* < 10 milliseconds indicates severe myocardial siderosis and a high risk of sudden cardiac death.
• Renal Toxicity: DFX can cause reversible creatinine elevation and Fanconi syndrome; baseline creatinine clearance, weekly serum creatinine, and urine protein/creatinine ratios are mandatory initially.
• Hepatic Toxicity: Requires transaminase monitoring every two weeks during the first month, then monthly.
• Gastrointestinal Toxicity: Severe mucosal ulceration and hemorrhage require immediate drug cessation if suspected.
• Sensory Toxicity: Annual audiograms and slit-lamp examinations are standard of care to monitor for high-frequency sensorineural hearing loss and cataracts.